文献速递肿瘤 PET/CT

开发新型分子探针通过正电子发射断层显像可视化肿瘤间皮素表达

Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-01-29

本研究开发了靶向间皮素(MSLN)的单域抗体探针[68Ga]Ga-NOTA-269-H4,在NCG小鼠OVCAR-8、SKOV-3及患者来源异种移植瘤模型中行microPET/CT显像与生物分布研究,显示该探针可清晰显示MSLN阳性肿瘤且特异性高,作者认为其是极具前景的PET探针。

要点

  • VHH 269-H4靶向MSLN的Kd值为0.3 nM,偶联NOTA后前体NOTA 269-H4的Kd值为1.1 nM。
  • [68Ga]Ga-NOTA-269-H4放射化学纯度>99%,室温孵育90分钟后稳定。
  • OVCAR-8异种移植瘤注射后30分钟放射性摄取为2.93 ± 0.39%ID/g,注射后90分钟肿瘤/血比值最高约3。

核心结论

  • 作者称其研究首次使用单域抗体片段通过PET清晰无创检测MSLN表达。
  • [68Ga]Ga-NOTA-269-H4是极具前景的PET探针,可在体内可视化MSLN表达,并有望监测肿瘤发展过程中的MSLN表达。

研究设计与样本

  • 通过使用MSLN第360至597位残基片段免疫羊驼获得VHH 269-H4。
  • 将p-SCN-Bn-NOTA偶联至VHH 269-H4得到前体NOTA 269-H4用于放射性标记,质谱测定螯合剂与VHH比例。
  • 用表面等离子共振测定VHH 269-H4与NOTA 269-H4的结合动力学,用抗间皮素单克隆抗体Anetumab行流式细胞术筛选MSLN阳性与阴性细胞系。
  • 放射性标记后分别用放射性薄层色谱和尺寸排阻色谱检测放射化学纯度与体外稳定性,饱和结合实验测定[68Ga]Ga-NOTA-269-H4的解离常数。
  • 在荷OVCAR-8、SKOV-3或患者来源异种移植瘤的NCG小鼠中行microPET/CT显像与生物分布研究。

主要发现

  • VHH 269-H4靶向MSLN的Kd值为0.3 nM;偶联后约27%和3.2%的VHH分别偶联一个和两个NOTA螯合剂,前体NOTA 269-H4的Kd值为1.1 nM。
  • 放射化学合成产率中等(34 ± 14%,n = 9,衰变校正),[68Ga]Ga-NOTA-269-H4放射化学纯度>99%,室温孵育90分钟后稳定,放射性配体对MSLN的结合亲和力保持在纳摩尔范围。
  • 流式细胞术显示OVCAR-8细胞MSLN高表达,SKOV-3细胞MSLN表达可忽略;microPET/CT中[68Ga]Ga-NOTA-269-H4在荷OVCAR-8异种移植瘤NCG小鼠显示清晰肿瘤显像,而SKOV-3异种移植瘤未见放射性聚集。
  • 生物分布研究中,[68Ga]Ga-NOTA-269-H4在OVCAR-8异种移植瘤注射后30分钟放射性摄取为2.93 ± 0.39%ID/g,注射后90分钟达到最高肿瘤/血比值(约3)。
  • 在荷患者来源异种移植瘤的NCG小鼠中,[68Ga]Ga-NOTA-269-H4通过microPET/CT显像能够无创检测MSLN表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mesothelin (MSLN) is an antigen that is overexpressed in various cancers, and its interaction with tumor-associated cancer antigen 125 plays a multifaceted role in tumor metastasis. The serum MSLN expression level can be detected using enzyme-linked immunosorbent assay; however, non-invasive visualization of its expression at the tumor site is currently lacking. Therefore, the aim of this study was to develop a molecular probe for imaging MSLN expression through positron emission tomography (PET). METHODS: VHH 269-H4 was obtained via immunization of llama using a fragment of MSLN from residue 360 to residue 597. S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was conjugated to VHH 269-H4 to yield precursor NOTA 269-H4 for radiolabeling. The chelator-to-VHH ratio was determined by mass spectrometry. The binding kinetics of VHH 269-H4 and NOTA 269-H4 were measured by surface plasmon resonance. Flow cytometry was carried out using the anti-mesothelin monoclonal antibody Anetumab to select MSLN-positive and MSLN-negative cell lines. After radiolabeling, the radiochemical purity and in vitro stability were tested by radio-thin-layer chromatography and size exclusion chromatography, respectively. A saturation binding assay was conducted to measure the dissociation constant (Kd) of [68Ga]Ga-NOTA-269-H4. By mircoPET/CT imaging and biodistribution studies, the in vivo performances of the novel tracer were investigated in NCG mice bearing OVCAR-8, SKOV-3, or patient-derived xenografts. RESULTS: VHH 269-H4 targeting MSLN was obtained with a Kd value of 0.3 nM. After conjugation, approximately 27% and 3.2% of VHH were coupled to one and two NOTA chelators, respectively. This yielded precursor NOTA 269-H4 with a Kd value of 1.1 nM. The radiochemistry was accomplished with moderate radiochemical yields (34 ± 14%, n = 9, decay-corrected). [68Ga]Ga-NOTA-269-H4 was obtained with high radiochemical purity (> 99%), and was stable after 90 min incubation at room temperature. The binding affinity of the radioligand towards MSLN was kept in the nanomolar range. Flow cytometry revealed that OVCAR-8 cells possess a high level of MSLN expression, while MSLN expression on SKOV-3 cells was negligible. Consistently, in microPET/CT imaging, [68Ga]Ga-NOTA-269-H4 demonstrated clear tumor visualization using NCG mice bearing OVCAR-8 xenografts, but no radioactivity accumulation was observed in SKOV-3 xenografts, suggesting a high specificity of the tracer in vivo. In biodistribution studies, [68Ga]Ga-NOTA-269-H4 displayed radioactivity accumulation of 2.93 ± 0.39%ID/g in OVCAR-8 xenografts at 30 min post-injection, and the highest tumor-to-blood ratio (~ 3) was achieved at 90 min post-injection. In NCG mice bearing patient-derived xenografts, [68Ga]Ga-NOTA-269-H4 was able to noninvasively detect MSLN expression via microPET/CT imaging. CONCLUSIONS: To our knowledge, our studies achieved the first-time to non-invasively detect MSLN expression clearly using a single domain antibody fragment. To sum up, [68Ga]Ga-NOTA-269-H4 is a highly promising PET probe to visualize MSLN expression in vivo and holds great potential to monitor MSLN expression during tumor development.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. He Y, Kong J, Wang Z, et al. Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography. Eur J Nucl Med Mol Imaging. 2025. PMID: 39878895. doi:10.1007/s00259-025-07087-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。